SpyGlass Pharma (SGP) vs Tandem Diabetes Care (TNDM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tandem Diabetes Care is the larger company by market cap ($1.22 billion vs $1.02 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SGP | TNDM |
|---|---|---|
| Share price | $30.43 | $17.46 |
| Market cap | $1.02B | $1.22B |
| 1-day change | -1.14% | +3.93% |
| YTD return | — | -20.56% |
| 1-year return | — | -17.95% |
| 5-year return | — | -86.53% |
| Forward P/E | — | 195.48 |
| EPS (TTM) | $-2.70 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.01B |
| Revenue growth (YoY) | — | +7.93% |
| Net income (latest FY) | $-39.87M | $-204.71M |
| Gross margin | — | 53.81% |
| Operating margin | — | -18.45% |
| Net margin | — | -20.17% |
| 52-week high | $39.92 | $29.65 |
| 52-week low | $17.06 | $12.26 |
| Distance from 52-week high | -23.77% | -41.11% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +53.37% | +55.21% |
| Average volume | 114.63K | 2.26M |
| Shares outstanding | 33.46M | 69.79M |
| Employees | 88 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About SpyGlass Pharma
SGP stock →SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
Health Care · Medical/Dental Instruments · 88 employees
About Tandem Diabetes Care
TNDM stock →Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
Health Care · Medical/Dental Instruments · 2,500 employees
SGP vs TNDM FAQ
Which is bigger, SpyGlass Pharma or Tandem Diabetes Care?
Tandem Diabetes Care (TNDM) is larger, with a market capitalization of $1.22B compared with $1.02B for SpyGlass Pharma (SGP).
Are SpyGlass Pharma and Tandem Diabetes Care in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.